Katarina Ziakova: The WFH Shared Decision – Making Tool Is Driving Critical Conversations in Haemophilia Care
Katarina Ziakova, Global Lead, Patient Advocacy for Rare Bleeding Disorders at Novo Nordisk, shared a post on LinkedIn:
“The WFH shared decision – making tool is helping drive a critical conversation in haemophilia care:how do we make treatment discussions more practical, more meaningful, and more centred on what matters most to the people living with haemophilia?
Proud that Novo Nordisk brought together Patient Organization Representatives and HCPs alongside WFH Congress 2026 for an educational event focused on shared decision-making.
What made this especially powerful was that our speakers represented three essential perspectives in haemophilia care: patients, physicians and nurses.
Together, we explored the key questions behind SDM – where to start, why it matters, and how it can be implemented in practice.
For me, this is what patient-centred care looks like: better conversations, stronger partnerships, and decisions that reflect real needs, priorities, and trade – offs.
Grateful for an evening of insight, exchange, and meaningful connection with the haemophilia community!”

Stay updated with Hemostasis Today.
-
Apr 23, 2026, 17:33Abdulaziz (Omar) Badran:
-
Apr 23, 2026, 17:19Kate Thomas: One Hour, One Donation, One Life Saved
-
Apr 23, 2026, 17:19Ameneh Eshghinejad: The First 72 Hours After SAH Are Critical for Balancing the Risks of Rebleeding and Thromboembolism
-
Apr 23, 2026, 17:14Paulus Kirchhof: Can We Improve Prevention of Cardiovascular Diseases?
-
Apr 23, 2026, 17:08Wolfgang Miesbach: 5‑Year Gene Therapy Data from WFH Congress 2026
-
Apr 23, 2026, 17:05Veronica Sanchez: The 2026 Guideline on the Management of Dyslipidemia
-
Apr 23, 2026, 16:57Hisam Siddiqi: Review of Interactive Cases by Blood Academy First Edition
-
Apr 23, 2026, 16:55Neda K.: When to Hold Antithrombotics and Use Bridging Therapy in Surgery
-
Apr 23, 2026, 16:39Amanda Thijsen։ How Do People Feel After Donating Blood Or Plasma?